Eli Lilly’s retatrutide — the first triple-hormone-receptor agonist (GLP-1, GIP, and glucagon) — posted striking Phase 3 results from the TRIUMPH program, with patients on the highest dose losing an average of 28.7% of their body weight at 68 weeks. That’s roughly 71 pounds.

The data span multiple trials. TRIUMPH-3 showed weight loss of 20.0% (9 mg dose) and 23.7% (12 mg dose). TRIUMPH-4, focused on patients with obesity and knee osteoarthritis, showed average weight loss of up to 26% along with a 75.8% reduction in knee pain scores — a finding that connects metabolic and musculoskeletal outcomes in a single trial.

These are the largest weight-loss numbers ever reported for any anti-obesity drug in Phase 3. They exceed tirzepatide (Zepbound), which set the previous standard at roughly 20–22%.

The complication: dysesthesia. This term describes an abnormal sense of touch — normal sensations that feel unusual or painful. In TRIUMPH data, dysesthesia appeared in 8.8% of patients on the 9 mg dose and 20.9% on the 12 mg dose, compared to 0.7% on placebo.

This signal is new. It was not reported in retatrutide’s earlier Phase 2 trial. Lilly has said the events were generally mild, self-limiting, and did not lead to significant treatment discontinuation. Analysts are watching for the signal in remaining TRIUMPH readouts — seven more Phase 3 results are expected through 2026.

The dysesthesia question will likely define retatrutide’s regulatory path. The efficacy case is overwhelming. The question is whether a 1-in-5 incidence of abnormal nerve sensation at the highest dose will require dose restrictions, additional monitoring, or labeling limitations.

Retatrutide has not yet been submitted for FDA approval. Based on current timelines, a filing could come in late 2026 or 2027.